Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
bispecific antibodies
Biotech
How Jeff Legos builds Pfizer’s oncology future
For the closely watched PD-1xVEGF competition, Jeff Legos’ strategy for Pfizer is anchored by three pillars: speed, breadth and novel combinations.
Angus Liu
Mar 4, 2026 2:00pm
Earendil pens $885M pact to use WuXi XDC's linker tech for ADCs
Feb 27, 2026 5:30am
FDA freezes enrollment in MacroGenics cancer trial after death
Feb 24, 2026 2:00pm
Astellas says 'I do' to Vir's T-cell engager in $1.7B deal
Feb 23, 2026 5:00pm
Angitia raises $130M to advance bone-building bispecifics
Feb 5, 2026 10:17am
Boehringer pens €1.05B deal for Simcere's IBD bispecific
Jan 27, 2026 7:30am
